Frontline evaluation: Atezolizumab–bevacizumab versus lenvatinib for BCLC stage B hepatocellular carcinoma exceeding the up‐to‐seven criteria by Masamichi Kimura, Koji Nishikawa, Jun Imamura, Kiminori Kimura

Get full text

Safety and tolerability of OP-724 in patients with haemophilia and liver cirrhosis due to HIV/HCV coinfection: an investigator-initiated, open-label, non-randomised, single-centre,... by Hiroyuki Gatanaga, Tsunamasa Watanabe, Masayuki Kurosaki, Masamichi Kimura, Jun Imamura, Ichiro Ieiri, Kiminori Kimura, Junko Tanuma, Mikio Yanase, Tomoyuki Endo, Hiroshi Yotsuyanagi

Get full text

Plasma extracellular vesicle microRNAs reflecting the therapeutic effect of the CBP/β-catenin inhibitor PRI-724 in patients with liver cirrhosis by Mayu Yoshida, Juntaro Matsuzaki, Koji Fujita, Masamichi Kimura, Tomohiro Umezu, Noi Tokuda, Tomoko Yamaguchi, Masahiko Kuroda, Takahiro Ochiya, Yoshimasa Saito, Kiminori Kimura

Get full text

Feasibility, safety and tolerability of the CREB-binding protein/β-catenin inhibitor OP-724 in patients with advanced primary biliary cholangitis: an investigator-initiated, open-l... by Eiichi Ogawa, Atsushi Tanaka, Kenichi Harada, Hiroshi Yatsuhashi, Kazumoto Murata, Masamichi Kimura, Jun Imamura, Masanao Saio, Yoshihiro Ikura, Kouichi Miura, Ichiro Ieiri, Kiminori Kimura

Get full text

Inhibition of CBP/β‐catenin signaling ameliorated fibrosis in cholestatic liver disease by Masamichi Kimura, Koji Nishikawa, Yosuke Osawa, Jun Imamura, Kenzaburo Yamaji, Kenichi Harada, Hiroshi Yatsuhashi, Kazumoto Murata, Kouichi Miura, Atsushi Tanaka, Tatsuya Kanto, Michinori Kohara, Terumi Kamisawa, Kiminori Kimura

Get full text